By Ben LevisohnSunTrust Robinson Humphrey’s Edward Nash and team offer five biotech stocks for the next six months:
Cempra (CEMP) ($50 PT), our top pick based on near-term clinical and commercial success potential. We recently met with management and it was reiterated that the second Phase III study of solithromycin in CABP (SOLITAIRE-IV) remains on track to report top-line data by […]
By Ben LevisohnSunTrust Robinson Humphrey’s Edward Nash and team offer five biotech stocks for the next six months:
Cempra (CEMP) ($50 PT), our top pick based on near-term clinical and commercial success potential. We recently met with management and it was reiterated that the second Phase III study of solithromycin in CABP (SOLITAIRE-IV) remains on track to report top-line data by […]
by The Brooklyn InvestorSo, (the sentence starts with “so” because this is a sort of ongoing discussion that’s been going on here for years) I’ve been thinking about the overall market again. Despite my telling people to ignore this and ignore that, I can’t help it; sometimes I think about this stuff. Well, it’s OK to think about it as […]
Read original article:
The New Money Masters: Fidelity Small Cap Stockpicker Chuck Myers
See which stocks are being affected by Social Media
[…]
Originally posted here:
Physicians Investing in BioTech- A Pro/Con
See which stocks are being affected by Social Media
[…]
Best Investor Play in the Hottest Biotech Stock Market on EarthCompanies / Tech StocksJun 17, 2015 – 08:01 AM GMTBy: Money_MorningMichael A. Robinson writes: Biotechnology is a big opportunity. And China is a big market.Combine the two and you have a big potential for investment profits.In today’s Strategic Tech Investor, I’m talking with Money Map Press Executive Editor William Patalon […]
Summary: Overall, fund managers’ asset allocations in June provide a confused view.On the one hand, fund managers raised cash to a 6-month high and reduced their global equity exposure to an 8-month low. Relative to recent history, this is contrarian bullish.Note, however, that most of the fall in their equity allocations came from further reducing emerging markets exposure; allocations to […]
CORAL GABLES, FL / ACCESSWIRE / June 16, 2015 / The summer still has yet to take hold of the penny stock market as trading continues to build momentum during June. Though much of the attention has been placed on the biotech sector’s volatility, value investors are still watching energy, technology, and precious metals for diversification as well as safe […]
Rxi Pharmaceuticals (NASDAQ:RXII)On June 9, 2015 shares of Rxi Pharmaceuticals went up 6% after the company reported that two new key patents were given to the company for use with their self-delivering sd-rxRNA technology platform. The new patents establish a few new details that enhance upon the company’s prospects:First the new patent is for a chemical modification that allows for […]
View the original here –
Research and Markets: Non Muscle Invasive …
See which stocks are being affected by Social Media
[…]
